
    
      Post-market, on label, multi-center, single arm, observational clinical trial of a
      prospective cohort of 300 subjects with primary or secondary, unilateral or bilateral, lower
      extremity lymphedema in the United States. All subjects will receive pneumatic compression
      treatment for 52 weeks.
    
  